RXRX
RECURSION PHARMACEUTICALS, INC.
Key Financials
Operating Income
$-648132000
↓ 35.3%
Revenue
$74.7M
↑ 26.9%
Net Income
$-644759000
↓ 39.1%
Total Assets
$1.5B
↑ 1.8%
EPS (Diluted)
$-1.44
↑ 14.8%
Total Liabilities
$343.3M
↓ 17.0%
Shareholders' Equity
$1.1B
↑ 9.3%
Cash & Equivalents
$743.3M
↑ 25.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 144 | 8/13/2026 | View on SEC |
| 144 | 8/12/2026 | View on SEC |
| 144 | 8/10/2026 | View on SEC |
| 144 | 8/7/2026 | View on SEC |
| SCHEDULE 13G | 8/7/2026 | View on SEC |
| 4 | 8/6/2026 | View on SEC |
| 10-Q | 8/5/2026 | View on SEC |
| 8-K | 8/5/2026 | View on SEC |
| 144 | 8/4/2026 | View on SEC |
| 144 | 8/4/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RXRX |
| Company Name | RECURSION PHARMACEUTICALS, INC. |
| CIK | 1601830 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (385) 269-0203 |